News
07-17-2017, 09:42 PM
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
More... (http://www.news-medical.net/news/20170718/FDA-approves-first-extended-adjuvant-therapy-to-lower-risk-of-breast-cancer-recurrence.aspx)
More... (http://www.news-medical.net/news/20170718/FDA-approves-first-extended-adjuvant-therapy-to-lower-risk-of-breast-cancer-recurrence.aspx)